Failing Bioprosthetic Aortic Valve: Valve-in-Valve or a Second Sternotomy
A decade-old surgical bioprosthesis is failing on schedule, but its small original size turns the obvious-seeming transcatheter fix into its own separate risk. The disagreement is about which uncertainty is worth accepting.
R.T., a 71-year-old man, drives himself to his cardiology follow-up the way he has for years — a habit left over from three decades behind the wheel of a long-haul truck, a routine he kept up even after his wife died two years ago and the passenger seat stopped getting used. He mentions, almost as an aside, that the walk up to his third-floor apartment has started to wind him in a way it didn't a year ago; he'd chalked it up to age until his surveillance echocardiogram — the kind he's had every year without incident since his aortic valve was replaced with a bioprosthesis a decade ago, at sixty-one — came back different.
The mean gradient across his valve has climbed from eighteen to forty-two millimeters of mercury over three years, with new leaflet thickening and restricted motion on imaging: structural valve deterioration, the failure mode every bioprosthesis eventually risks, arriving at the early end of the ten-to-fifteen years a bioprosthesis implanted in a patient in his early sixties is commonly quoted to last, since age at implantation is the strongest single predictor of how fast these valves degenerate. What complicates the next decision more than the diagnosis itself is the valve he already has. It's a twenty-one-millimeter surgical prosthesis — small enough that threading a second, transcatheter valve inside it risks leaving him with a smaller effective opening than either valve was ever meant to have on its own, a mismatch that can blunt exactly the symptomatic relief he's hoping for. A second open operation would avoid that risk entirely, at the cost of a second sternotomy in a man now a decade older, with mild kidney impairment and atrial fibrillation that wasn't part of the picture the first time around. He is not frail and not urgent — walking daily, driving himself, in no acute distress — which is exactly why this is a real choice rather than an obvious one.
Reviewing a decade-old valve's surveillance echo
Valve-in-valve avoids a second sternotomy entirely in a man who is now ten years older, with atrial fibrillation and chronic kidney disease neither of which existed at his first operation. A transfemoral approach is very well tolerated at his age, with recovery measured in days rather than weeks. I take the mismatch risk seriously with a 21-millimeter surgical valve, but there are sizing and technique choices — including valve fracture of the original ring in select cases — that can mitigate it meaningfully rather than making it a fixed outcome.
A 21-millimeter surgical valve is precisely the anatomy where valve-in-valve risks severe patient-prosthesis mismatch, and registry data link severe mismatch to worse long-term hemodynamics and mortality — not a theoretical concern, a measured one. He is not frail. He is functionally independent, walking daily, and a reoperative sternotomy in a patient like that carries real but acceptably low risk. A fresh, appropriately sized surgical valve solves the mismatch problem permanently instead of working around it with fracture techniques that add their own procedural complexity.
I'd also point out that mitigation techniques for mismatch are exactly that — mitigation, not elimination. We'd be choosing a strategy built around managing a problem a new surgical valve simply wouldn't have.
Whichever procedure is chosen, his antithrombotic course differs in ways worth naming now rather than after the fact. After valve-in-valve, current guidance leans toward continuing his existing apixaban for atrial fibrillation without adding an antiplatelet for the valve itself, though there's an evolving, not fully settled literature on subclinical leaflet thrombosis after transcatheter valves that some centers manage with closer imaging surveillance rather than a change in anticoagulation. After redo surgery, the immediate postoperative course typically adds bridging heparin around the operation itself. His CKD is worth naming precisely rather than loosely: apixaban's dose reduction in atrial fibrillation turns on two of three criteria — age 80 or older, weight 60 kilograms or less, creatinine 1.5 milligrams per deciliter or higher — and an eGFR in the fifties is not itself one of them, so he stays on the full 5-milligram twice-daily dose. What this anatomy actually needs before either specialist commits to a recommendation is CT-based valve and annular sizing to quantify the real mismatch risk rather than estimating it from the original implant size alone — that's a Heart Team decision, not a two-specialist one.
Agreed: CT-based valve and annular sizing to quantify the actual patient-prosthesis mismatch risk before any final decision, formal Heart Team review once sizing is available, and continuation of apixaban in the meantime.
Not agreed, and the reason the sizing study carries real weight rather than being a formality:
The transcatheter pathway is favored, weighing his age and new comorbidities against a quantified, acceptable mismatch risk.
Redo surgical replacement becomes the recommended path despite the second sternotomy, on the surgeon's original argument.
The interventional cardiologist and the surgeon left holding different defaults about which risk is more acceptable to accept up front — a disagreement the sizing data, not either specialist's preference alone, is meant to resolve.